Applied Genetic Technologies Corp. Daily Stock Analysis

Daily Stock Analysis, AGTC, Applied Genetic Technologies Corp, priceseries

Applied Genetic Technologies Corp. Daily Stock Analysis
Stock Information
Open
1.71
Close
1.67
High
1.74
Low
1.63
Previous Close
1.72
Daily Price Gain
-0.05
YTD High
2.83
YTD High Date
Feb 10, 2022
YTD Low
1.40
YTD Low Date
Jan 24, 2022
YTD Price Change
-0.39
YTD Gain
-18.93%
52 Week High
6.41
52 Week High Date
Mar 19, 2021
52 Week Low
1.40
52 Week Low Date
Jan 24, 2022
52 Week Price Change
-2.99
52 Week Gain
-64.16%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Jan 2. 2018
3.75
Jan 16. 2018
4.04
9 Trading Days
7.64%
Link
LONG
Jan 22. 2018
4.15
Feb 1. 2018
4.57
8 Trading Days
10.17%
Link
LONG
Feb 28. 2018
3.85
Mar 12. 2018
4.34
8 Trading Days
12.84%
Link
LONG
Apr 11. 2018
4.00
Apr 25. 2018
4.67
10 Trading Days
16.85%
Link
LONG
May 14. 2018
5.05
May 22. 2018
5.36
6 Trading Days
6.17%
Link
LONG
Sep 18. 2018
4.25
Oct 8. 2018
6.24
14 Trading Days
46.82%
Link
LONG
Aug 29. 2019
2.98
Sep 19. 2019
3.67
14 Trading Days
23.03%
Link
LONG
Dec 19. 2019
2.96
Jan 2. 2020
4.16
8 Trading Days
40.62%
Link
LONG
Apr 8. 2020
3.37
Apr 29. 2020
3.88
14 Trading Days
15.18%
Link
LONG
Jun 15. 2020
5.14
Jun 26. 2020
6.22
9 Trading Days
20.98%
Link
LONG
Feb 11. 2021
5.90
Feb 22. 2021
6.47
6 Trading Days
9.70%
Link
LONG
Feb 3. 2022
2.01
Feb 15. 2022
2.23
8 Trading Days
11.06%
Link
Company Information
Stock Symbol
AGTC
Exchange
NasdaqGM
Company URL
http://www.agtc.com
Company Phone
386-462-2204
CEO
Susan B. Washer
Headquarters
Florida
Business Address
14193 NW 119TH TERRACE, SUITE #10, ALACHUA, FL 32615
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001273636
About

Applied Genetic Technologies Corp. is a clinical-stage biotechnology company, which engages in the development of gene therapy products designed to transform the lives of patients with severe diseases in ophthalmology. Its product candidates are designed to treat X-linked retinoschisis, Achromatopsia, and X-linked retinitis pigmentosa. The company was founded by Richard Jude Samulski, Nicholas Muzyczka, William W. Hauswirth, Terence R. Flotte, and Barry J. Byrne on January 19, 1999 and is headquartered in Alachua, FL.

Description

Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops genetic therapies to treat patients with inherited diseases. Its lead products consist of four ophthalmology development programs across three targets, including X linked retinoschisis (XLRS) that is in a Phase I/II clinical trials for the treatment of an inherited retinal disease; X-linked retinitis pigmentosa (XLRP), which is enrolling patients in a Phase I/II clinical trials; and achromatopsia (ACHM) that is enrolling patients in a Phase I/II clinical trials. Applied Genetic Technologies Corporation has collaboration agreements with Biogen MA, Inc.; 4D Molecular Therapeutics; and Synpromics Limited. The company was founded in 1999 and is headquartered in Alachua, Florida.

TCHANNELS® is a Registered Trademark with USPTO

Some images used on this site have been taken from Unsplash

Legal Information

Useful Links

Contact Us

PO Box 2574, Sunnyvale
California 94087-0574, USA
Phone: 408-940-5056
Email: Click to send us an Email

Risks of Algorithmic Trading: Before investing please read our disclosure on Risks of Algorithmic Trading.

DISCLAIMER All investments entail inherent risk. This research seeks to assist investors in determining when to buy and when to sell to attempt to maximize profits or minimize losses. All final investment decisions are yours and as a result you could make or lose money. priceSeries.com, its employees and/or its affiliates and family members may from time to time take positions in the open market or otherwise with respect to the securities discussed. priceSeries.com, its employees and/or affiliates do not have stock ownership equal to or greater than 1% of the outstanding stock of the covered company nor does any employee of priceSeries.com sit on the Board of Directors of any covered company. priceSeries.com is not a broker/dealer, and the firm does not underwrite securities, manage assets or perform investment banking activities. The statements made herein include information obtained from sources believed to be reliable, but no independent verification has been made and we do not guarantee its accuracy or completeness.

U.S. Government Required Disclaimer - Commodity Futures Trading Commission
Futures and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.

CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.

2016 © priceSeries.com All Rights Reserved. Privacy Policy | Subscriber Agreement | Risks of Algorithmic Trading